Immutep


Management Team


    John B. Hawken

    President and CEO

    Mr. John B. Hawken is a specialist in the management of start-up biotechnology companies funded by VC firms. He successfully managed several biotechnology start-up's in France such as the drug delivery company Diatos, the antimicrobial peptides company EntoMed and the cellular gene therapy company Neurotech. Before starting his career in the field of Biotechnology, Mr Hawken was the Managing Director of two French subsidiaries of international chemical groups and held senior positions in Shell International Chemicals. He has a degree in Chemistry (Oxford University) and holds an MBA (INSEAD).



    Frédéric Triebel

    Scientific and Medical Director

    Dr. Frédéric Triebel was Professor in Immunology and Biotechnology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 140 publications and 16 patents.

© 2002 Immutep, S.A.
Press Release
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate
image Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
image Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
image Immutep S.A. announced today the first administration of IMP321 in ...